iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Safety and pharmacokinetics of DUR-928 in patients with non-alcoholic steatohepatitis-A Phase 1b study
 
 
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
 
W. KEMP1, J. SHAH2, M. J. KIM2, D. ELLIS2, J. BROWN2, F. THEEUWES2, W.Q. LIN2 1. Department of Gastroenterology, Alfred Hospital, Melbourne, Australia 2. DURECT Corporation, Cupertino, United States

0526171

0526172

0526173

0526174

0526175

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org